IGF-1 LR3
Preclinical — Animal / cell-model data onlyWhat it is
A long-acting analogue of insulin-like growth factor 1. A potent growth factor with significant safety concerns.
IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1 — a potent growth factor. Its potency brings real hypoglycaemia risk and a theoretical risk of promoting unwanted tissue growth.
Research context
Studied in relation to:
- Growth-factor research
Points in its favour in the literature:
- Potent, long-acting IGF-1 activity
Caveats and unknowns:
- Hypoglycaemia risk
- Potential to promote unwanted tissue/tumour growth
- Prohibited in sport
- Unlicensed for human use
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature.
Reported half-life~20–30 h
Published clinical / research context (not instructions)Reported research ~20–50 mcg daily. Potent — carries hypoglycaemia risk.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)Often reconstituted in bacteriostatic water or 0.6% acetic acid, e.g. 1 mg + 1 mL → 1 mg/mL (1000 mcg/mL).
Available research formats
| Strength | SKU |
|---|---|
| 0.1mg | IG01 |
| 1mg | IG1 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.